Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524352 | 0.91 | EPHX2 (0.48) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL1790270 | 0.84 | — | — | |
| SCHEMBL27183 | 0.81 | ALDH1A1 (0.56) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL14317238 | 0.81 | EPHX2 (0.55) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL21325280 | 0.81 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL83783 | 0.81 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL4550276 | 0.81 | SMN1; SMN2 (0.52) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL11850495 | 0.81 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL1563627 | 0.79 | CYP1A2 (0.48) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL21472126 | 0.79 | CYP1A2 (0.48) | CYP1A2TDP1EPHX2EPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916776-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2023-04-04 | — | — | CN | claimed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | claimed |
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | claimed |
| EP-2222664-B1 | CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-1730131-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-05-09 | — | — | EP | claimed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| US-8039441-B2 | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-18 | — | — | US | claimed |
| WO-2004108710-A1 | 4-PYRIMIDINYL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004069827-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069250-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069249-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| WO-2003048159-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003047584-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | claimed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | CYP1A2 4765/4885TDP1 645/4885EPHX2 4067/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CYP1A2 3585/4885TDP1 2692/4885EPHX2 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.